© 2022 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
April 18, 2016
Real-world dose adjustments occurred in patients with primary immunodeficiency who switched from intravenous immunoglobulin to subcutaneous immunoglobulin 20%, with resulting implications for payers, patients, and plasma collection and supply.